New research of over 300 documents reveals a mixed bag of evidence surrounding the controversial 340B Drug Pricing Program’s impact on the U.S. healthcare system, a study published Nov. 22 in JAMA Health Forum found.
Read the full post on Becker's Hospital Review - Healthcare News
